Breath Biomarkers and Biosecurity in the Era of Eradication
These days an infected individual can carry a new or emerging disease around the world before symptoms are obvious. Efforts to control and eradicate ancient scourges such as TB or malaria are also hampered by the difficulty of identifying asymptomatic carriers. This talk will describe some of the biosecurity problems inherent in the diagnosis of early stage or asymptomatic infectious diseases and the role that new diagnostic modalities can play in bolstering biosecurity. It will focus on the discovery of breath biomarkers of early stage malaria and describe biosensor technologies being developed to make point of departure/entry screening more feasible, effective and robust.
DR STEPHEN TROWELL
CSIRO Health and Biosecurity
Stephen has 30 years’ experience leading multidisciplinary, multi-investigator research projects. Stephen holds a Natural Sciences degree from Cambridge University, majoring in Biochemistry, and a Ph.D. in visual neuroscience from the Australian National University.
Stephen led the development of Cybernose®/Cybertongue® technology for CSIRO and is a key member of the analytical team that discovered thioether biomarkers for early stage malaria. Stephen is currently leading the technical development and commercialisation of CYBERTONGUE® technology for point of need food diagnostic and related applications.
Stephen’s practical achievements include development and commercialisation of The LepTon™ Test Kit – an immunodiagnostic kit used to manage insecticide resistance in the cotton industry, and The Insect Extract Library – a novel source of bioactive natural products.
Stephen has more than 100 publications, 54 of them full papers in refereed international journals and is inventor on 17 patent families. Stephen is a graduate of the Australian Defence Science and Technology Organisation’s Executive Leadership Program.
Please see the following for up to date listings of Stephen’s publications: